2连板丰山集团：截至2025年上半年 钠离子电解液销售额占公司合并报表营业收入的比例为0.01%

Core Viewpoint - The company, Fengshan Group, clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite recent media speculation linking it to the "solid-state battery" concept [1] Business Operations - The company’s main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes accounting for a relatively small proportion of sales [1] - As of the first half of 2025, the sales revenue from sodium-ion electrolytes is expected to represent only 0.01% of the company's consolidated operating income [1] Research and Development - The recent important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the research and development project commissioned by the company [1] - The collaboration with Tsinghua University is still in the preliminary research and development phase, with a small contract amount, and the technical development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]